Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants
Status:
Terminated
Trial end date:
2018-01-18
Target enrollment:
Participant gender:
Summary
The study hypothesis is that short-term low dose cyclophosphamide therapy will be effective
in resolving inflammation in patients with late phase antibody-mediated rejection refractory
to current standard of care treatment.